Auro Laboratories Limited Stock Price Today (NSE: AUROLAB)

Auro Laboratories Limited

251.15+1.05 (+0.42%)
Market Closed

Fundamental Score

...

Auro Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Auro Laboratories Limited share price today is 251.15, up +0.42% on NSE/BSE as of 22 September 2026. Auro Laboratories Limited (AUROLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 156.53 (Cr). The 52-week high for AUROLAB share price is 317.00 and the 52-week low is 159.00. At a P/E ratio of 33.41x, AUROLAB is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 7.90% and a debt-to-equity ratio of 1.37.

Auro Laboratories Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
267.80
Low
226.00
Volume
6.4K
Change
+9.39%

Auro Laboratories Limited share price chart: 9.39% return over the past month. 52-week high ₹317.00, 52-week low ₹159.00.

Auro Laboratories Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
250.00258.70245.55250.102.52K (Cr)
249.00259.00243.90249.904.95K (Cr)
250.00254.50237.05244.401.44K (Cr)
249.90253.80239.00247.901.47K (Cr)
253.80261.90236.20243.202.99K (Cr)
254.00261.75247.00253.8038.21K (Cr)
254.00260.70246.05256.953.02K (Cr)
256.75260.00252.00256.752.17K (Cr)
261.00262.00256.15256.756.82K (Cr)
255.00262.50249.75257.6510.63K (Cr)

Auro Laboratories Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
236.00267.80226.00250.10+5.97%
232.05259.95223.10232.00-0.02%
259.85265.00230.00231.10-11.06%
278.00278.00240.30252.10-9.32%
240.00285.90240.00277.50+15.63%
265.00279.80239.00239.10-9.77%
291.95299.00252.00265.00-9.23%
222.05317.00220.25291.95+31.48%
244.00248.00199.95226.65-7.11%
248.15274.00236.15249.45+0.52%
197.00269.20159.00248.15+25.96%
245.00245.00182.30193.30-21.10%

Returns & Performance

Poor

Return on Equity (ROE)

7.90%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

10.66%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

15.95%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Auro Laboratories Limited Valuation Check

Average

Price to Earnings (P/E)

33.41x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

52.18%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.01%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

1095.26%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

216.13%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-10.74%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-12.70%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

-12.70%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.37x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

2.13x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-0.47 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Auro Laboratories Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AUROLAB across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Operating Margins (15.95%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (1095.26%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (216.13%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Balanced Promoter Holding (52.18%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

9 factors identified

Below-Average Return on Equity (7.90%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Limited Growth History (-10.74% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (-12.70% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (-12.70% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Elevated Debt Levels (D/E: 1.37)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (2.13x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-0.47 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.01%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Auro Laboratories Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Auro Laboratories Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
34.7/100
251
₹156.53
33.4
Average
7.90%
Poor
10.66%
Average
1.4
Average
-12.70%
Poor
-10.74%
Poor
0.00%
66.4/100
1862
₹446629.70
36.9
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9452
₹250478.00
85.8
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4966
₹168062.31
79.3
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112444.66
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1376
₹111135.92
33.0
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1944
₹104997.59
95.9
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1669
₹96028.51
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1140
₹95190.00
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2079
₹95075.99
17.2
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2270
₹93763.39
45.9
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Auro Laboratories Limited Quarterly Performance

Latest quarterly metrics for AUROLAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

216.13%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

1095.26%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-10.74%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

-12.70%

Compounded annual net profit growth over 5 years

Auro Laboratories Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for AUROLAB — calculated from daily price history

73RSI 14
Overbought — RSI 73

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
242
▲ Price above SMA 50 — Short-term bullish
SMA 200
255
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
5K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Auro Laboratories Limited Financial Statements

Annual income statement, balance sheet and cash flow for Auro Laboratories Limited (AUROLAB) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Auro Laboratories Limited

Loading latest quarterly results...

About AUROLAB (Auro Laboratories Limited)

Auro Laboratories Limited is a dynamic and innovative pharmaceutical company dedicated to the development, manufacture, and distribution of high-quality pharmaceutical products. Co...mmitted to improving global health, Auro Laboratories specializes in crafting a diverse portfolio of active pharmaceutical ingredients (APIs) and advanced drug intermediates. Leveraging cutting-edge research and development capabilities, the company focuses on creating novel formulations and improving existing treatment options. With a robust manufacturing infrastructure, Auro Laboratories adheres to the most stringent international quality standards, ensuring the safety and efficacy of every product. Driven by a team of skilled scientists, engineers, and professionals, Auro Laboratories seeks to address unmet medical needs and make a significant impact on healthcare worldwide. Auro Laboratories Limited is recognized for its strategic approach to pharmaceutical manufacturing, focusing on therapeutic areas with significant patient needs. The company's extensive product range encompasses various therapeutic segments, including treatments for allergies, musculoskeletal disorders, metabolic diseases, and infectious diseases. Auro Laboratories develops and manufactures therapies targeting prevalent conditions such as diabetes, fungal infections, and inflammatory ailments, offering affordable and accessible solutions to healthcare providers and patients alike. Furthermore, the company produces essential supplements, including those addressing iron deficiency and iodine deficiencies, ensuring the availability of vital nutrients in vulnerable populations. Dedicated to expanding its reach and impact, Auro Laboratories continuously invests in new product development and market expansion strategies. Auro Laboratories Limited demonstrates unwavering commitment to sustainable and ethical business practices. The company prioritizes environmental responsibility through implementing eco-friendly manufacturing processes and minimizing its environmental footprint. Auro Laboratories upholds the highest ethical standards in all aspects of its operations, fostering a culture of integrity and transparency. By adhering to rigorous regulatory guidelines and quality control measures, Auro Laboratories ensures that every product meets the highest standards of safety, efficacy, and purity. The company emphasizes building strong relationships with its partners, suppliers, and stakeholders based on trust, collaboration, and mutual respect. Auro Laboratories is dedicated to creating a positive impact on society by providing access to affordable, high-quality medicines and promoting responsible business practices.

Company Details

Symbol:AUROLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Sharat Sahadeolal Deorah B.Com.
Executive Chairman & MD
Mr. Siddhartha Sharat Deorah MBA
Whole Time Director
Mr. Kiran Suresh Kulkarni
Additional Whole Time Director

AUROLAB Share Price: Frequently Asked Questions

What is the current share price of Auro Laboratories Limited?

Auro Laboratories Limited (AUROLAB) trades at ₹251.15 on NSE and BSE. Market cap ₹156.53 (Cr). Educational data only.

What is the P/E ratio of Auro Laboratories Limited?

Auro Laboratories Limited has a P/E of 33.41x vs industry average 34.89x.

What is the Bull Run score for Auro Laboratories Limited?

Auro Laboratories Limited has a Bull Run score of 34.7/100 based on 25+ financial parameters.

Does Auro Laboratories Limited pay dividends?

Auro Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Auro Laboratories Limited?

Auro Laboratories Limited has ROE of 7.90%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Auro Laboratories Limited?

Auro Laboratories Limited has debt-to-equity of 1.37.

Is Auro Laboratories Limited a good investment?

Bull Run gives Auro Laboratories Limited a score of 34.7/100. This is not investment advice — consult a SEBI-registered advisor.